Literature DB >> 28351199

Pharmacological Management of Psychiatric Symptoms in Frontotemporal Dementia: A Systematic Review.

Massimiliano Buoli1, Marta Serati1, Alice Caldiroli1, Daniela Galimberti2, Elio Scarpini2, Alfredo Carlo Altamura1.   

Abstract

Psychiatric symptoms in patients with frontotemporal dementia (FTD) are highly prevalent and may complicate clinical management of these patients. Purpose of the present article is to present and discuss available data about the pharmacological treatment of psychiatric symptoms in patients with FTD. A research in the main database sources has been conducted to obtain an overview of the pharmacological management of psychiatric symptoms in patients with FTD. The search strategy included the following terms-"FTD and psychiatry," "FTD and behavioural disturbances," and "FTD and treatment". Pathophysiology of psychiatric symptoms in FTD is different from other types of dementia. Although drugs for Alzheimer disease appear to be ineffective for the treatment of psychiatric symptoms of FTD, preliminary evidence supports a possible usefulness of serotonergic antidepressants for these patients. Data are too scanty to draw definitive conclusions, but antidepressant treatment, particularly with serotonergic compounds, may improve psychiatric symptoms in patients with FTD. Large observational studies are needed to confirm this preliminary evidence, and a lot of effort and collaboration between neurologists and psychiatrists will be definitely crucial for future research of effective treatments for FTD.

Entities:  

Keywords:  frontotemporal dementia (FTD); pharmacotherapy; psychiatric symptoms

Mesh:

Substances:

Year:  2017        PMID: 28351199     DOI: 10.1177/0891988717700506

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  1 in total

Review 1.  Development of disease-modifying drugs for frontotemporal dementia spectrum disorders.

Authors:  Francesco Panza; Bruno P Imbimbo; Madia Lozupone; Davide Seripa; Antonio Daniele; Mark Watling; Gianluigi Giannelli
Journal:  Nat Rev Neurol       Date:  2020-03-23       Impact factor: 42.937

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.